Search clinical trials for: Leish-111f MPL-SE vaccine

Total 54 results

IDRI
Bill and Melinda Gates Foundation

Completed

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Mucosal Leishmaniasis

Leishmaniasis, Mucocutaneous

Peru
IDRI
Bill and Melinda Gates Foundation

Completed

Study to Evaluate the Leish-111f + MPL-SE Vaccine in Healthy Adults Not Previously Exposed to Leishmania Parasite

Cutaneous Leishmaniasis

Colombia
IDRI
Bill and Melinda Gates Foundation

Completed

Safety Study to Evaluate the Leish-111f + MPL-SE Vaccine in the Prevention of Cutaneous Leishmaniasis in Healthy Subjects Previously Exposed to the Leishmania Parasite

Cutaneous Leishmaniasis

Colombia
IDRI
Bill and Melinda Gates Foundation

Completed

Open-Label Safety Study of Three-Antigen Leishmania Polyprotein With Adjuvant MPL-SE in Healthy Adults in India

Visceral Leishmaniasis | Post-kala-azar Dermal Leishmaniasis

India
IDRI
Bill and Melinda Gates Foundation

Completed

Study to Evaluate the Leish-111F + MPL-SE Vaccine in the Treatment of Cutaneous Leishmaniasis

Leishmaniasis, Cutaneous

Brazil
IDRI

Completed

Safety and Immunogenicity of the LEISH-F2 + MPL-SE Vaccine With SSG for Patients With PKDL

Post Kala Azar Dermal Leishmaniasis

Sudan
National Institute of Allergy and Infectious Diseases...

Completed

LEISH-F3 + GLA-SE and the LEISH-F3 + MPL-SE Vaccine

Leishmaniasis

United States
IDRI
Bill and Melinda Gates Foundation

Completed

Phase 1 LEISH-F3 + SLA-SE Vaccine Trial in Healthy Adult Volunteers

Visceral Leishmaniasis

United States
IDRI

Completed

Phase 1 LEISH-F3 Vaccine Trial in Healthy Adult Volunteers

Leishmaniasis

United States
IDRI

Completed

A Study of the Efficacy and Safety of the LEISH-F2 + MPL-SE Vaccine for Treatment of Cutaneous Leishmaniasis

Cutaneous Leishmaniasis

Peru
GlaxoSmithKline

Completed

Safety and Immunogenicity of GSK Bio's Candidate HBV-MPL Vaccines Compared to Engerix™-B, in Healthy Adolescents

Hepatitis B

Germany
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of Herpes Simplex (gD) Candidate Vaccine With/Without Adjuvant

Prophylaxis Herpes Simplex

Belgium
AIDS Clinical Trials Group
National Institute of Allergy and Infectious Diseases (NIAID)

Not yet recruiting

Therapeutic ID93 + GLA-SE Vaccination in Participants With Rifampicin-Susceptible Pulmonary TB

Tuberculosis, Pulmonary
GlaxoSmithKline

Completed

Consistency of 3 Consecutive Lots of a Novel HBV Vaccine With Single-blind Safety Evaluation Using Engerix™-B as Control

Hepatitis B
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Pre-liver Transplant Patients 18 Years of Age

Hepatitis B
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 18-40 y

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Study Comparing Immunogenicity, Reactogenicity and Safety of GSK Bios' HBV-MPL Vaccine With That of Engerix™-B in Adults

Hepatitis B

Belgium, Canada, Sweden
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of Various Formulations of Recombinant Hepatitis B Vaccine With Different Adjuvants

Hepatitis B

Belgium
Oswaldo Cruz Foundation

Recruiting

Anti-Schistosomiasis Sm14-vaccine in Senegal

Vaccination; Infection | Schistosomiasis Mansoni | Schistosomiasis Haematobium

Senegal
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Adults (15-40 Yrs).

Hepatitis B

Denmark, Belgium
GlaxoSmithKline

Completed

Comparing Immunogenicity and Safety of Different Formulations of HBV-MPL Vaccine With Engerix™-B in Adults Aged 19-40 y

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity & Reactogenicity of HBV-MPL Vaccine and Engerix™-B in Healthy Adults Following 2 Different Schedules

Hepatitis B

Belgium
Themis Bioscience GmbH
Walter Reed Army Institute of Research (WRAIR)

Completed

Study of a Live Attenuated Chikungunya Vaccine in a Previously Epidemic Area

Chikungunya

Puerto Rico
Medicago
McGill University Health Centre/Research Institute of the McGill University... and other collaborators

Completed

Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.

RNA Virus Infections | Virus Diseases | Respiratory Tract Infections | Respiratory Tract Diseases

Canada
GlaxoSmithKline

Completed

Immunogenicity and Safety of GSK Biologicals' HBV-MPL Vaccine (2 Doses), and of Engerix™-B (3 Doses) in Healthy Adults

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Safety and Immunogenicity of 3 Lots of GSK Biologicals' HBV-MPL Vaccine and Engerix™-B in Healthy Volunteers ≥ 15y

Hepatitis B

Australia, Czech Republic, Germany, Italy, Netherlands, Switzerland, United Kingdom
Leiden University Medical Center
MRC/UVRI and LSHTM Uganda Research Unit; Texas Tech University Health Sciences...

Not yet recruiting

Sm-p80 Schistosomiasis Challenge Study

Schistosomiasis | Schistosoma Mansoni
GlaxoSmithKline

Completed

Immunogenicity and Safety of an Adjuvanted HBV Vaccine Compared to Engerix™-B, in a Non-responder Population ≥ 15y

Hepatitis B
GlaxoSmithKline

Completed

Immunogenicity and Safety of a Novel Adjuvanted HBV Vaccine in Healthy Volunteers Positive for the HLA-DQ2 Genotype

Hepatitis B
Walvax Biotechnology Co., Ltd.

Completed

A Study to Demonstrate Non-inferior Immunogenicity of Yuxi Walvax MPV ACYW® Vaccine in Healthy Subjects Aged 2-10 Years

Neisseria Meningitides Meningitis

Mali
Beijing Minhai Biotechnology Co., Ltd

Completed

Immunogenicity and Safety of Meningococcal (A, C, Y and W135) Conjugate Vaccine

Meningitis

China
GlaxoSmithKline

Completed

Evaluation of Immunogenicity, Reactogenicity and Safety of HBV-MPL Vaccine vs Engerix™-B, in Haemodialysis Patients

Hepatitis B

Belgium
GlaxoSmithKline

Completed

Comparison of Safety, Immuno- and Reactogenicity of MPL-Adjuvanted Recombinant Hepatitis B Vaccine to That of Engerix™-B

Hepatitis B

Austria
GlaxoSmithKline

Completed

Immunogenicity and Reactogenicity of MPL Adjuvanted Recombinant Hepatitis B- Vaccine and Engerix™-B in Adult Non-Responders

Hepatitis B

Belgium
Fundacion Clinic per a la Recerca Biomédica
Polymun Scientific GmbH

Recruiting

Clinical Trial to Evaluate the Safety and Immunogenicity of Recombinant HIV-1 Envelope Protein SOSIP v8.2 763 Vaccine, Adjuvanted With MPLA Liposomes, in Healthy, HIV-Uninfected Adults (HIVAC-FOUND)

Healthy

Spain
GlaxoSmithKline

Completed

Safety, Immunogenicity and Reactogenicity of Recombinant Hepatitis B Vaccine (Adjuvanted & New Formulation) and Engerix™-B

Hepatitis B

Austria
Worcester HIV Vaccine
Brigham and Women's Hospital; Access to Advanced Health Institute (AAHI)

Completed

Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults

HIV Infections

United States
National Institute of Allergy and Infectious Diseases...

Completed

Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults

HIV Infections

United States
MRC/UVRI and LSHTM Uganda Research Unit
King's College London; Karolinska Institutet; Gilead Sciences; Imperial College... and other collaborators

Enrolling by invitation

A Combination Efficacy Study in Africa of Two DNA-MVA-Env Protein or DNA-Env Protein HIV-1 Vaccine Regimens With PrEP (PrEPVacc)

HIV Infections

Uganda
GlaxoSmithKline

Completed

HerpeVac Trial for Young Women

Herpes Simplex Infection

United States, Canada
National Institute of Allergy and Infectious Diseases...

Completed

Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults

HIV Infections

United States, Thailand
International Vaccine Institute
Massachusetts General Hospital; EuBiologics Co.,Ltd

Recruiting

Dose Escalation Study to Evaluate the Safety and Immunogenicity of the Cholera Conjugate Vaccine in Healthy Adults

Cholera Vaccination Reaction

Korea, Republic of
Ronald Levy
National Institutes of Health (NIH)

Completed

Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL

Lymphoma, Mantle-Cell

United States
Instituto de Investigação em Imunologia
Butantan Institute

Unknown

Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)

Cancer. | Melanoma. | Ovarian Cancer. | Lung Cancer.

Brazil
National Institute of Allergy and Infectious Diseases...
Rho Federal Systems Division, Inc.; Autoimmunity Centers of Excellence

Completed

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

Systemic Lupus Erythematosus (SLE) | Multiple Sclerosis (MS) | Rheumatoid Arthritis (RA) | Juvenile Dermatomyositis (JDM) | Juvenile Idiopathic Arthritis (JIA) | Pemphigus Vulgaris | Systemic Sclerosis (SSc) | Pediatric SLE | Pediatric-Onset Multiple Sclerosis (POMS)

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission

Stage IIA Fallopian Tube Cancer | Stage IIA Ovarian Cancer | Stage IIB Fallopian Tube Cancer | Stage IIB Ovarian Cancer | Stage IIC Fallopian Tube Cancer | Stage IIC Ovarian Cancer | Stage IIIA Fallopian Tube Cancer | Stage IIIA Ovarian Cancer | Stage IIIA Primary Peritoneal Cancer | Stage IIIB Fallopian... and other conditions

United States
Craig L Slingluff, Jr

Completed

Evaluation of a Multi-phosphopeptide Vaccine Plus PolyICLC in Participants With High Risk and Advanced Malignancies (Mel59)

Melanoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ

Breast Ductal Carcinoma In Situ

United States
Charite University, Berlin, Germany
Company HeVaTech

Completed

Cupping in Osteoarthritis of the Knee

Osteoarthritis of the Knee

Germany
Novartis

Completed

Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients

Kidney Transplantation | Graft Rejection

United States

3

Subscribe